MeSH term
Frequency | Condition_Probility | Humans | 1035 | 0.0 |
Child, Preschool | 181 | 2.0 |
Male | 456 | 0.0 |
Neoplasm Recurrence, Local | 5 | 1.0 |
Neurofibromatosis 1/*complications/diagnosis/genetics | 2 | 100.0 |
Pedigree | 71 | 1.0 |
Research Support, Non-U.S. Gov't | 607 | 0.0 |
Base Sequence | 257 | 0.0 |
CCAAT-Enhancer-Binding Proteins/*physiology | 5 | 41.0 |
Caco-2 Cells | 2 | 0.0 |
Gene Expression Regulation | 16 | 0.0 |
Oligodeoxyribonucleotides | 12 | 1.0 |
Promoter Regions (Genetics)/*physiology | 2 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 263 | 0.0 |
Transcription Factors/*physiology | 5 | 1.0 |
Animals | 272 | 0.0 |
Chromosome Mapping | 59 | 0.0 |
*Chromosomes, Human, Pair 17 | 75 | 14.0 |
DNA Primers | 34 | 0.0 |
English Abstract | 65 | 0.0 |
In Situ Hybridization, Fluorescence | 46 | 1.0 |
Karyotyping | 15 | 0.0 |
Polymerase Chain Reaction | 120 | 1.0 |
Adaptation, Psychological | 2 | 4.0 |
Brain/*physiology | 2 | 1.0 |
Female | 448 | 0.0 |
DNA Mutational Analysis | 63 | 1.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Italy | 5 | 0.0 |
Mutation | 83 | 0.0 |
Neurofibromatosis 1/*genetics/pathology | 20 | 90.0 |
Neurofibromin 1/*genetics | 16 | 100.0 |
Polymorphism, Single-Stranded Conformational | 23 | 1.0 |
Protein Biosynthesis | 14 | 1.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 31 | 0.0 |
DNA, Neoplasm/analysis | 14 | 1.0 |
Genes, Neurofibromatosis 1 | 32 | 96.0 |
Genes, p53 | 6 | 1.0 |
Kinetics | 17 | 0.0 |
Microsatellite Repeats | 15 | 1.0 |
Mitotic Index | 2 | 1.0 |
Neoplasm Invasiveness | 10 | 0.0 |
Adolescent | 219 | 1.0 |
Adult | 299 | 0.0 |
Aged | 88 | 0.0 |
Child | 260 | 1.0 |
Contrast Media | 4 | 7.0 |
Gadolinium DTPA/diagnostic use | 2 | 16.0 |
Magnetic Resonance Imaging | 69 | 6.0 |
Middle Aged | 152 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Combined Modality Therapy | 4 | 0.0 |
Infant | 94 | 1.0 |
Infant, Newborn | 37 | 0.0 |
Neurofibromatosis 1/*complications | 38 | 95.0 |
Retrospective Studies | 35 | 1.0 |
Treatment Outcome | 18 | 0.0 |
*Chromosomes, Human, Pair 1 | 3 | 0.0 |
Genetic Predisposition to Disease | 11 | 0.0 |
Recurrence | 4 | 0.0 |
*Alternative Splicing | 11 | 1.0 |
Cells, Cultured | 63 | 0.0 |
*Gene Expression | 4 | 0.0 |
Genes, Neurofibromatosis 1/physiology | 3 | 100.0 |
Mice | 136 | 0.0 |
Neurofibromatosis 1/*genetics | 177 | 97.0 |
Tissue Distribution | 11 | 0.0 |
Chromosomes, Human, Pair 17/genetics | 16 | 9.0 |
Chromosomes, Human, Pair 22/genetics | 4 | 5.0 |
Mutation/genetics | 10 | 0.0 |
Neurofibromatosis 1/diagnosis/genetics | 2 | 66.0 |
United States | 3 | 0.0 |
Age Distribution | 3 | 0.0 |
Comparative Study | 72 | 0.0 |
England/epidemiology | 2 | 3.0 |
Magnetic Resonance Imaging/methods | 2 | 2.0 |
Survival Rate | 13 | 0.0 |
Chimera | 2 | 1.0 |
Forecasting | 3 | 0.0 |
Genes, Neurofibromatosis 2 | 2 | 8.0 |
Genotype | 25 | 0.0 |
Hyperplasia | 4 | 1.0 |
Mice, Knockout | 20 | 0.0 |
Neurilemmoma/etiology | 2 | 100.0 |
*Neurofibromatosis 1/genetics/pathology | 2 | 100.0 |
Neurofibromin 1/physiology | 2 | 100.0 |
Schwann Cells/pathology | 3 | 23.0 |
Spinal Cord Neoplasms/*genetics | 2 | 25.0 |
Aged, 80 and over | 20 | 0.0 |
*Chromosome Aberrations | 10 | 1.0 |
Chromosomes, Human, Pair 19/genetics | 2 | 1.0 |
Nerve Sheath Tumors/*genetics/pathology | 3 | 60.0 |
Neurilemmoma/genetics/pathology | 2 | 25.0 |
Neurofibromatosis 1/genetics/pathology | 4 | 80.0 |
Nucleic Acid Hybridization | 9 | 0.0 |
Mosaicism/genetics | 2 | 9.0 |
Skin/pathology | 5 | 1.0 |
Disease Models, Animal | 15 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
*Genes, Neurofibromatosis 1 | 174 | 99.0 |
Genes, Reporter | 7 | 0.0 |
Mice, Inbred C57BL | 17 | 0.0 |
Mice, Inbred CBA | 2 | 0.0 |
Mice, Transgenic | 17 | 0.0 |
Alternative Splicing/*genetics | 5 | 3.0 |
Exons/genetics | 21 | 1.0 |
Organ Specificity | 8 | 0.0 |
Protein Isoforms/genetics | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 78 | 0.0 |
Schwann Cells/metabolism | 4 | 16.0 |
Temperature | 4 | 0.0 |
Time Factors | 18 | 0.0 |
Gene Expression Regulation, Neoplastic | 14 | 0.0 |
Genes, Tumor Suppressor | 13 | 1.0 |
Immunohistochemistry | 42 | 0.0 |
Nerve Sheath Tumors/genetics/*metabolism | 2 | 100.0 |
Biopsy | 9 | 0.0 |
Fatal Outcome | 8 | 1.0 |
Neurofibromatosis 1/*complications/diagnosis | 7 | 100.0 |
Tomography, X-Ray Computed | 23 | 3.0 |
Neurofibromatosis 1/complications/*pathology | 7 | 100.0 |
Adenosine Triphosphate/metabolism | 3 | 0.0 |
Neurofibromatosis 1/*physiopathology | 4 | 100.0 |
*Signal Transduction | 7 | 0.0 |
Chick Embryo | 3 | 0.0 |
Sequence Homology, Amino Acid | 13 | 0.0 |
Amino Acid Sequence | 79 | 0.0 |
Cell Nucleus/metabolism | 12 | 0.0 |
Molecular Sequence Data | 266 | 0.0 |
Neurofibromatosis 1/*genetics/metabolism | 7 | 87.0 |
Protein Structure, Secondary | 2 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/genetics | 2 | 2.0 |
Transfection | 38 | 0.0 |
Tumor Cells, Cultured | 68 | 0.0 |
Case-Control Studies | 14 | 0.0 |
Observer Variation | 3 | 2.0 |
Prevalence | 17 | 1.0 |
Cognition | 2 | 3.0 |
Databases, Factual | 3 | 1.0 |
Interviews | 2 | 4.0 |
Gene Expression Profiling | 4 | 0.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Prognosis | 29 | 0.0 |
Cell Line, Tumor | 7 | 0.0 |
Gene Expression | 27 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
In Situ Hybridization | 11 | 0.0 |
Leukemia, Myelomonocytic, Chronic/*genetics | 3 | 30.0 |
Loss of Heterozygosity | 16 | 1.0 |
*Point Mutation | 15 | 1.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 3 | 0.0 |
Alleles | 61 | 0.0 |
Autistic Disorder/*genetics | 2 | 3.0 |
Gene Frequency | 16 | 0.0 |
Japan | 4 | 0.0 |
Microsatellite Repeats/genetics | 5 | 1.0 |
Polymorphism, Genetic | 33 | 0.0 |
Incidence | 19 | 1.0 |
Longitudinal Studies | 5 | 0.0 |
Risk Assessment | 3 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Follow-Up Studies | 37 | 1.0 |
Intelligence Tests | 6 | 11.0 |
Neuropsychological Tests | 10 | 3.0 |
Reference Values | 16 | 0.0 |
Social Behavior | 2 | 10.0 |
Cerebral Angiography | 4 | 14.0 |
Cell Line | 50 | 0.0 |
Cloning, Molecular | 55 | 0.0 |
Exons | 53 | 1.0 |
Promoter Regions (Genetics) | 33 | 0.0 |
Chromosomes, Human, Pair 17 | 37 | 11.0 |
Consanguinity | 2 | 0.0 |
DNA, Viral/analysis | 2 | 0.0 |
Papillomavirus, Human/genetics | 2 | 5.0 |
5' Untranslated Regions | 2 | 1.0 |
*Gene Duplication | 5 | 3.0 |
Genetic Markers | 53 | 1.0 |
Haplotypes | 11 | 0.0 |
*Linkage Disequilibrium | 3 | 1.0 |
Quebec | 2 | 3.0 |
Cognition/*physiology | 2 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Models, Biological | 8 | 0.0 |
Neurofibromin 1/metabolism | 5 | 71.0 |
Signal Transduction/*physiology | 5 | 0.0 |
ras Proteins/metabolism | 8 | 5.0 |
Immunoenzyme Techniques | 6 | 0.0 |
Neurofibromatosis 1/*genetics/metabolism/pathology | 7 | 100.0 |
Neurofibromin 1/*genetics/metabolism | 3 | 100.0 |
S100 Proteins/metabolism | 7 | 6.0 |
Cafe-au-Lait Spots/etiology | 2 | 100.0 |
Cell Transformation, Neoplastic/genetics | 7 | 2.0 |
Genes, Dominant | 7 | 0.0 |
Guanosine Triphosphate/metabolism | 13 | 4.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Centromere/*genetics | 2 | 6.0 |
Chromosomes, Human, Pair 15/*genetics | 3 | 3.0 |
Gene Order/genetics | 2 | 5.0 |
Mental Retardation/genetics | 5 | 4.0 |
Neoplasm Proteins/genetics | 3 | 0.0 |
Polymorphism, Genetic/genetics | 5 | 0.0 |
Pseudogenes/genetics | 3 | 4.0 |
Calcium/pharmacology | 3 | 1.0 |
Cell Differentiation | 13 | 0.0 |
Cytochalasin D/pharmacology | 2 | 2.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Binding Sites | 44 | 0.0 |
Cattle | 11 | 0.0 |
DNA/genetics/metabolism | 9 | 2.0 |
Hela Cells | 28 | 0.0 |
Plasmids | 18 | 1.0 |
*Promoter Regions (Genetics) | 41 | 1.0 |
TATA Box | 6 | 1.0 |
Transcription Factors/*metabolism | 22 | 1.0 |
Neurofibromatosis 1/*complications/pathology/*surgery | 2 | 100.0 |
*Genes, Neurofibromatosis 2 | 3 | 3.0 |
*Genes, Tumor Suppressor | 12 | 1.0 |
Neoplasms/*genetics | 5 | 1.0 |
*RNA Splicing | 6 | 2.0 |
RNA, Messenger/analysis | 11 | 0.0 |
Repressor Proteins/*genetics | 4 | 1.0 |
Blotting, Western | 19 | 0.0 |
Cell Proliferation | 3 | 1.0 |
Cytokines/metabolism | 3 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Phosphorylation | 11 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
RNA/metabolism | 4 | 0.0 |
Retroviridae/genetics | 3 | 0.0 |
*Transcription, Genetic | 22 | 1.0 |
Alternative Splicing | 11 | 1.0 |
*DNA-Binding Proteins | 10 | 0.0 |
*Gene Expression Regulation | 14 | 0.0 |
Rats | 73 | 0.0 |
*Transcription Factors | 21 | 1.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Neurofibromin 1/*metabolism | 2 | 100.0 |
Age Factors | 21 | 0.0 |
Cohort Studies | 10 | 0.0 |
Neurofibromatosis 1/*pathology | 22 | 95.0 |
Facial Neoplasms/genetics | 2 | 66.0 |
Neurofibroma, Plexiform/etiology/*genetics | 2 | 100.0 |
Neurofibromatosis 1/*complications/pathology | 5 | 100.0 |
Hamartoma/diagnosis | 2 | 50.0 |
Magnetic Resonance Imaging/*methods | 4 | 5.0 |
Optic Chiasm/pathology | 3 | 100.0 |
Optic Nerve/pathology | 3 | 42.0 |
Gene Expression/drug effects | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 10 | 0.0 |
Transcription Factor AP-1/metabolism | 3 | 1.0 |
Transcription Factors/*genetics | 8 | 0.0 |
Carrier Proteins/*genetics | 4 | 0.0 |
DNA/genetics | 17 | 0.0 |
Membrane Glycoproteins/*genetics | 4 | 0.0 |
*Membrane Transport Proteins | 3 | 0.0 |
*Nerve Tissue Proteins | 4 | 0.0 |
Neurofibromatosis 1/complications/*genetics | 13 | 100.0 |
Chromosomes, Human, Pair 22 | 11 | 7.0 |
Intelligence/*genetics | 2 | 13.0 |
Mice, Neurologic Mutants | 3 | 2.0 |
Neurofibromatosis 1/diagnosis/*genetics | 11 | 100.0 |
Neurofibromin 1/genetics | 6 | 100.0 |
Signal Transduction/genetics | 4 | 1.0 |
Adenylate Cyclase/*metabolism | 2 | 3.0 |
GTP-Binding Proteins/genetics/*physiology | 2 | 11.0 |
Mutation/physiology | 2 | 1.0 |
Diagnosis, Differential | 27 | 1.0 |
Tumor Markers, Biological | 4 | 0.0 |
Family Health | 9 | 0.0 |
Gene Deletion | 21 | 1.0 |
Linkage (Genetics) | 22 | 0.0 |
Linkage Disequilibrium | 5 | 0.0 |
Polymorphism, Restriction Fragment Length | 34 | 1.0 |
Fibronectins/metabolism | 2 | 1.0 |
*Heterozygote | 2 | 0.0 |
Neurofibromatosis 1/*genetics/physiopathology | 3 | 100.0 |
Blotting, Southern | 31 | 1.0 |
*Gene Deletion | 32 | 3.0 |
CCAAT-Enhancer-Binding Proteins/*metabolism | 3 | 10.0 |
DNA Footprinting | 8 | 2.0 |
Liver/metabolism | 8 | 0.0 |
Luciferases/genetics | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Transcription, Genetic | 47 | 0.0 |
*Cell Transformation, Neoplastic | 4 | 0.0 |
Schwann Cells/cytology/metabolism | 2 | 22.0 |
Visual Acuity | 5 | 3.0 |
Base Composition | 6 | 2.0 |
*Chromosomes, Human, Pair 22 | 7 | 3.0 |
Linkage Disequilibrium/*genetics | 2 | 2.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Sequence Analysis, DNA | 21 | 0.0 |
Brain Neoplasms/*pathology | 6 | 8.0 |
Magnetic Resonance Spectroscopy/*methods | 2 | 8.0 |
Protons | 2 | 2.0 |
Codon | 8 | 1.0 |
Nerve Sheath Tumors/*genetics | 7 | 70.0 |
Protein Subunits | 2 | 0.0 |
RNA, Messenger/analysis/genetics | 5 | 1.0 |
Sequence Alignment | 18 | 0.0 |
Sequence Deletion/genetics | 3 | 1.0 |
Ultraviolet Rays | 3 | 0.0 |
Brain/metabolism/pathology | 2 | 1.0 |
Brain Neoplasms/*diagnosis/pathology | 2 | 40.0 |
*Magnetic Resonance Spectroscopy | 2 | 4.0 |
Prospective Studies | 10 | 0.0 |
Loss of Heterozygosity/*genetics | 4 | 4.0 |
Melanoma/etiology/*genetics | 2 | 22.0 |
Mutation, Missense/genetics | 4 | 2.0 |
Neurofibromatoses/*genetics/*pathology | 2 | 100.0 |
RNA Splice Sites/genetics | 2 | 1.0 |
Neurofibromatosis 1/genetics/*pathology | 6 | 85.0 |
Neurofibromatosis 1/*complications/epidemiology/pathology | 2 | 100.0 |
3T3 Cells | 14 | 0.0 |
5' Flanking Region/genetics | 2 | 2.0 |
Exons/*genetics | 7 | 2.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Introns/genetics | 8 | 1.0 |
Monosaccharide Transport Proteins/*genetics | 2 | 10.0 |
Phenotype | 52 | 0.0 |
Promoter Regions (Genetics)/*genetics | 12 | 1.0 |
Testis/metabolism | 2 | 0.0 |
Bone Marrow/pathology | 6 | 1.0 |
Neurofibromatosis 1/*diagnosis | 21 | 100.0 |
Neurofibromatosis 1/*complications/diagnosis/physiopathology | 2 | 100.0 |
Spinal Cord/pathology | 2 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 11 | 0.0 |
Electrophoretic Mobility Shift Assay | 3 | 0.0 |
Papillomavirus, Human/*genetics | 4 | 5.0 |
Variation (Genetics) | 7 | 0.0 |
Neurofibromatosis 1/complications/diagnosis | 2 | 100.0 |
Neurofibromatosis 2/complications/diagnosis | 2 | 66.0 |
Chromosomes, Human, Pair 17/*genetics | 10 | 5.0 |
Genes, Neurofibromatosis 1/*genetics | 65 | 100.0 |
Genetic Screening/methods | 2 | 1.0 |
*Mutation | 48 | 1.0 |
Nerve Tissue Proteins/genetics | 13 | 4.0 |
Neurofibromatosis 1/*diagnosis/*genetics | 4 | 100.0 |
Neurofibromin 1 | 160 | 94.0 |
Risk | 3 | 0.0 |
Syndrome | 14 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Rabbits | 5 | 0.0 |
*Nerve Growth Factors | 2 | 1.0 |
Neurofibromatosis 1/*genetics/*pathology | 8 | 88.0 |
Signal Transduction | 25 | 0.0 |
Nerve Tissue Proteins/*genetics | 19 | 3.0 |
Cell Division | 15 | 0.0 |
*Drosophila Proteins | 7 | 0.0 |
Genes, Insect | 2 | 3.0 |
COS Cells | 4 | 0.0 |
Cell-Free System | 3 | 1.0 |
Electrophoresis | 3 | 1.0 |
Simian virus 40/genetics | 3 | 2.0 |
Chromosome Banding | 8 | 1.0 |
DNA-Binding Proteins/*genetics | 10 | 0.0 |
*Nuclear Proteins | 3 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Antigens, Nuclear | 4 | 2.0 |
Genes, Retinoblastoma | 4 | 4.0 |
*Germ-Line Mutation | 6 | 1.0 |
Ki-67 Antigen | 2 | 0.0 |
Nuclear Proteins/genetics | 3 | 1.0 |
Cytogenetic Analysis | 2 | 1.0 |
Genes, Tumor Suppressor/genetics | 6 | 3.0 |
Leukocyte Count | 2 | 0.0 |
*Loss of Heterozygosity | 8 | 2.0 |
Biological Markers/analysis | 3 | 0.0 |
Microscopy, Electron | 5 | 0.0 |
Tumor Markers, Biological/analysis | 4 | 0.0 |
Chromosomes, Human, Pair 14/*genetics | 2 | 2.0 |
Chromosomes, Human, Pair 2/*genetics | 2 | 1.0 |
Chromosomes, Human, Pair 22/*genetics | 2 | 2.0 |
DNA Primers/genetics | 12 | 0.0 |
Gene Duplication | 4 | 2.0 |
Hybrid Cells | 24 | 1.0 |
Neurofibromatosis 1/genetics | 25 | 83.0 |
*Pseudogenes | 4 | 2.0 |
Translocation, Genetic | 11 | 1.0 |
Chromosomes, Artificial, Yeast/genetics | 2 | 1.0 |
Expressed Sequence Tags | 4 | 0.0 |
Antigens, CD34/analysis | 3 | 0.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Neurofibromatosis 1/*metabolism/pathology | 4 | 100.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Astrocytoma/*genetics/pathology | 5 | 21.0 |
Crosses, Genetic | 7 | 1.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Models, Genetic | 13 | 0.0 |
Disease Progression | 15 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
DNA Primers/chemistry | 6 | 0.0 |
*Muscle Proteins | 2 | 0.0 |
Nuclear Proteins/analysis | 3 | 1.0 |
Protein p53/analysis | 2 | 0.0 |
*Chromosome Deletion | 16 | 2.0 |
DNA/analysis | 10 | 1.0 |
Evolution, Molecular | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 27 | 1.0 |
Protein p53/genetics/metabolism | 3 | 3.0 |
*Alleles | 10 | 0.0 |
Introns/*genetics | 4 | 2.0 |
Microsatellite Repeats/*genetics | 3 | 1.0 |
DNA/chemistry/genetics | 6 | 0.0 |
*Recombination, Genetic | 4 | 1.0 |
*Magnetic Resonance Imaging | 16 | 9.0 |
Neoplasms, Multiple Primary/*pathology | 2 | 12.0 |
Peripheral Nervous System Neoplasms/*genetics/metabolism | 2 | 100.0 |
S100 Proteins/*metabolism | 3 | 5.0 |
ras Proteins/genetics/metabolism | 2 | 8.0 |
Neurofibromatosis 1/diagnosis/*genetics/therapy | 2 | 100.0 |
ras GTPase-Activating Proteins/genetics | 2 | 66.0 |
Fibroblasts | 3 | 0.0 |
Genetic Markers/genetics | 6 | 1.0 |
Germ-Line Mutation/genetics | 3 | 4.0 |
Neurofibroma/*genetics/pathology | 4 | 66.0 |
Point Mutation/*genetics | 4 | 1.0 |
RNA Splicing/genetics | 3 | 2.0 |
Elasticity | 2 | 4.0 |
Multivariate Analysis | 3 | 0.0 |
Neurofibromatosis 1/complications/*physiopathology | 3 | 100.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Haplotypes/genetics | 6 | 1.0 |
Loss of Heterozygosity/genetics | 5 | 3.0 |
Mutation/*genetics | 11 | 0.0 |
Genes, p53/genetics | 6 | 2.0 |
Molecular Biology/methods | 2 | 7.0 |
Peripheral Nervous System Neoplasms/*genetics | 4 | 80.0 |
Protein p53/metabolism | 2 | 0.0 |
Pregnancy | 11 | 0.0 |
Neoplasms, Multiple Primary/*diagnosis | 2 | 40.0 |
Terminology | 2 | 1.0 |
Brain/metabolism | 6 | 0.0 |
Brain Chemistry | 5 | 1.0 |
Macromolecular Substances | 4 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Binding Sites/genetics | 9 | 0.0 |
Binding, Competitive | 6 | 0.0 |
Consensus Sequence | 12 | 1.0 |
Gene Expression Regulation/drug effects | 5 | 0.0 |
Promoter Regions (Genetics)/drug effects | 3 | 2.0 |
Rats, Wistar | 8 | 0.0 |
Transcription Factors | 2 | 2.0 |
*Tomography, X-Ray Computed | 5 | 5.0 |
*Genes, ras | 13 | 6.0 |
Glioma/*genetics | 2 | 2.0 |
Cafe-au-Lait Spots/epidemiology | 2 | 100.0 |
Neurofibromatosis 1/*epidemiology | 3 | 100.0 |
Hippel-Lindau Disease/genetics | 2 | 4.0 |
Multiple Endocrine Neoplasia Type 2a/genetics | 3 | 10.0 |
Pheochromocytoma/*genetics | 6 | 14.0 |
Proteins/genetics | 13 | 1.0 |
Proto-Oncogene Proteins/genetics | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics | 3 | 2.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Brain Neoplasms/*complications/*pathology | 2 | 100.0 |
Cell Line, Transformed | 12 | 0.0 |
Sequence Deletion | 27 | 1.0 |
Cell Movement | 2 | 0.0 |
Nerve Tissue Proteins/chemistry | 2 | 10.0 |
Neurofibromin 2 | 6 | 6.0 |
Life Expectancy | 2 | 4.0 |
United States/epidemiology | 2 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
Open Reading Frames | 5 | 0.0 |
Mental Retardation/*genetics | 3 | 1.0 |
Membrane Proteins/genetics | 4 | 1.0 |
Neurofibromatosis 2/*genetics/pathology | 2 | 20.0 |
Proto-Oncogene Protein p21(ras)/metabolism | 9 | 11.0 |
Polymerase Chain Reaction/methods | 9 | 0.0 |
*Gene Expression Regulation, Neoplastic | 12 | 0.0 |
Point Mutation | 15 | 0.0 |
Rats, Sprague-Dawley | 9 | 0.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
DNA/metabolism | 7 | 0.0 |
*Gene Silencing | 6 | 3.0 |
Protein Binding | 23 | 0.0 |
Saccharomyces cerevisiae/genetics | 6 | 1.0 |
Brain Neoplasms/*diagnosis | 6 | 60.0 |
Astrocytoma/*pathology | 2 | 12.0 |
Frontal Lobe/*pathology | 2 | 22.0 |
Neurofibromatosis 1/complications/*diagnosis | 5 | 83.0 |
Morbidity | 2 | 3.0 |
Neural Conduction/physiology | 2 | 5.0 |
Severity of Illness Index | 10 | 0.0 |
*Adaptation, Psychological | 2 | 6.0 |
Comorbidity | 6 | 2.0 |
Educational Status | 2 | 3.0 |
Intelligence | 5 | 16.0 |
Siblings | 2 | 2.0 |
Social Class | 3 | 8.0 |
*DNA Methylation | 3 | 0.0 |
DNA-Binding Proteins/metabolism | 11 | 0.0 |
Neurofibroma/*genetics | 10 | 66.0 |
*Repressor Proteins | 6 | 0.0 |
Transcription Factor, Sp1/metabolism | 2 | 0.0 |
*Linkage (Genetics) | 17 | 1.0 |
Lod Score | 15 | 1.0 |
Cyclic AMP/pharmacology | 3 | 2.0 |
Forskolin/pharmacology | 8 | 2.0 |
Gene Expression Regulation, Enzymologic/drug effects | 2 | 1.0 |
Mutagenesis, Site-Directed | 17 | 0.0 |
Regulatory Sequences, Nucleic Acid | 11 | 1.0 |
Structure-Activity Relationship | 5 | 0.0 |
Genes, Neurofibromatosis 1/genetics | 13 | 100.0 |
Genes, p53/*genetics | 4 | 1.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
DNA, Neoplasm/genetics | 13 | 1.0 |
Melanoma/*genetics | 2 | 1.0 |
Lumbosacral Region | 2 | 6.0 |
Neurofibromatosis 1/epidemiology/*genetics | 8 | 100.0 |
Risk Factors | 15 | 0.0 |
Sex Factors | 7 | 0.0 |
DNA-Binding Proteins/*metabolism | 18 | 0.0 |
Nuclear Proteins/metabolism | 5 | 0.0 |
Oligonucleotide Probes | 13 | 2.0 |
Templates, Genetic | 4 | 2.0 |
Cell Division/drug effects | 11 | 0.0 |
Cell Separation | 3 | 0.0 |
Germ-Line Mutation | 7 | 1.0 |
Blood | 2 | 1.0 |
Calcium-Binding Proteins/*genetics | 2 | 2.0 |
Liver/*metabolism | 4 | 0.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Glioma/etiology | 4 | 100.0 |
Leukemia/etiology | 2 | 22.0 |
Neurofibromatosis 1/*complications/therapy | 2 | 100.0 |
Odds Ratio | 3 | 0.0 |
Cell Extracts | 2 | 1.0 |
Histones/*metabolism | 2 | 1.0 |
Neurofibromatosis 1/*complications/diagnosis/epidemiology | 2 | 100.0 |
Ileal Neoplasms/*pathology | 2 | 66.0 |
Neoplasms, Multiple Primary | 2 | 13.0 |
Neurofibroma/*pathology | 4 | 57.0 |
Fibroblasts/metabolism | 10 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 3 | 0.0 |
Mice, Mutant Strains | 8 | 1.0 |
Protein Conformation | 3 | 0.0 |
Recombinant Proteins/metabolism | 8 | 0.0 |
Electrocardiography | 2 | 0.0 |
Neurofibromatosis 1/*complications/*diagnosis | 3 | 75.0 |
*Frameshift Mutation | 4 | 2.0 |
CCAAT-Enhancer-Binding Proteins/genetics/*metabolism | 2 | 10.0 |
Cell Nucleus/*metabolism | 3 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Neurofibromatosis 1/blood/*genetics/pathology | 2 | 100.0 |
Alu Elements/*genetics | 2 | 6.0 |
Gene Frequency/genetics | 3 | 0.0 |
Genome, Human | 4 | 0.0 |
Trinucleotide Repeat Expansion/genetics | 2 | 5.0 |
Astrocytoma/*genetics/metabolism/pathology | 2 | 16.0 |
Brain Neoplasms/*genetics/metabolism/pathology | 2 | 8.0 |
Nerve Tissue Proteins/deficiency/*genetics | 2 | 22.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
ras GTPase-Activating Proteins/metabolism | 2 | 15.0 |
Gene Expression Regulation, Neoplastic/physiology | 3 | 2.0 |
Genetic Screening | 5 | 0.0 |
Finland/epidemiology | 2 | 1.0 |
CpG Islands | 2 | 0.0 |
Down-Regulation | 4 | 0.0 |
Sulfites/metabolism | 2 | 20.0 |
Dosage Compensation (Genetics) | 4 | 2.0 |
Neoplasms, Second Primary | 3 | 23.0 |
Heterozygote | 27 | 0.0 |
Variation (Genetics)/genetics | 6 | 3.0 |
Cerebellum/pathology | 3 | 10.0 |
Mice, Nude | 3 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Nerve Tissue Proteins/biosynthesis | 2 | 8.0 |
Species Specificity | 7 | 0.0 |
Visual Pathways | 3 | 100.0 |
Cerebellum/pathology/surgery | 2 | 100.0 |
Blood Pressure | 3 | 0.0 |
Glioma/*diagnosis | 3 | 75.0 |
Optic Nerve Neoplasms/*diagnosis | 5 | 100.0 |
Facies | 2 | 7.0 |
Leukocytes/metabolism | 3 | 2.0 |
*Mosaicism | 8 | 14.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Apoptosis/genetics | 2 | 0.0 |
Cell Differentiation/genetics | 5 | 1.0 |
Down-Regulation/genetics | 2 | 3.0 |
Neurofibroma, Plexiform/genetics | 4 | 100.0 |
RNA, Messenger/genetics | 11 | 0.0 |
Skin Neoplasms/genetics | 2 | 6.0 |
Molecular Biology | 8 | 3.0 |
Gene Expression/*genetics | 3 | 2.0 |
Abnormalities, Multiple/genetics | 2 | 2.0 |
Chromosome Deletion | 15 | 2.0 |
Glutathione Transferase/genetics/metabolism | 3 | 2.0 |
Recombinant Fusion Proteins/genetics/metabolism | 4 | 0.0 |
Schwann Cells/*chemistry | 2 | 50.0 |
Learning Disorders/etiology | 2 | 66.0 |
DNA, Neoplasm/*genetics | 4 | 1.0 |
Genetic Counseling | 6 | 3.0 |
Genetics, Population | 4 | 1.0 |
Heterozygote Detection | 6 | 1.0 |
Neurofibromatoses/*genetics | 7 | 77.0 |
DNA Mutational Analysis/methods | 4 | 1.0 |
*Sequence Deletion | 12 | 3.0 |
Blotting, Northern | 14 | 0.0 |
Fishes/*genetics | 2 | 10.0 |
Genes, Structural/*genetics | 2 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
DNA Mutational Analysis/*methods | 4 | 3.0 |
Frameshift Mutation | 6 | 1.0 |
Heteroduplex Analysis | 2 | 2.0 |
Introns | 25 | 1.0 |
Mutation, Missense | 3 | 0.0 |
Neurofibroma/genetics | 4 | 80.0 |
Peripheral Nervous System Neoplasms/genetics | 2 | 66.0 |
Embryonic and Fetal Development/*genetics | 2 | 2.0 |
Wound Healing/*genetics | 2 | 20.0 |
DNA-Binding Proteins/genetics/*metabolism | 7 | 0.0 |
Transcription Factors/genetics/*metabolism | 7 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Chromosome Breakage | 2 | 2.0 |
Contig Mapping | 3 | 1.0 |
Physical Chromosome Mapping | 5 | 1.0 |
Sequence Tagged Sites | 3 | 1.0 |
*CCAAT-Enhancer-Binding Proteins | 27 | 20.0 |
Hepatocyte Growth Factor/genetics/*metabolism | 2 | 9.0 |
Lymphocytes/metabolism | 3 | 1.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Proteins/*genetics | 48 | 3.0 |
RNA Splicing/*genetics | 4 | 4.0 |
Oncogene Proteins, Viral/*genetics | 2 | 3.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 2 | 2.0 |
Cell Transformation, Neoplastic | 6 | 1.0 |
Neurofibromatosis 1/*metabolism | 7 | 77.0 |
DNA Fingerprinting | 3 | 2.0 |
Phylogeny | 4 | 0.0 |
Chromosome Breakage/genetics | 2 | 3.0 |
Sequence Deletion/*genetics | 2 | 1.0 |
Neural Crest/metabolism | 2 | 22.0 |
Proteins/metabolism | 2 | 0.0 |
Tubulin/metabolism | 4 | 4.0 |
Myelin-Associated Glycoprotein/*genetics | 3 | 16.0 |
Predictive Value of Tests | 4 | 0.0 |
Sensitivity and Specificity | 8 | 0.0 |
*Evolution, Molecular | 3 | 0.0 |
Genes, Wilms Tumor | 2 | 3.0 |
*Exons | 13 | 3.0 |
Neurofibromatosis 1/*genetics/metabolism/*pathology | 2 | 100.0 |
Point Mutation/genetics | 3 | 1.0 |
Population Surveillance | 2 | 1.0 |
Gene Conversion | 2 | 3.0 |
Multigene Family | 4 | 0.0 |
*Genomics | 2 | 7.0 |
Primates/genetics | 2 | 4.0 |
Preoperative Care | 2 | 1.0 |
Chromosomes, Artificial, Yeast | 5 | 1.0 |
Conserved Sequence/genetics | 3 | 1.0 |
Chromosomes, Human, Pair 15 | 2 | 1.0 |
*Translocation, Genetic | 13 | 1.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Animals, Genetically Modified | 2 | 0.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Enzyme Activation | 10 | 0.0 |
GTP-Binding Proteins/metabolism | 2 | 0.0 |
Insect Proteins/genetics/*physiology | 2 | 25.0 |
Fungal Proteins/*genetics/metabolism | 2 | 6.0 |
*GTPase-Activating Proteins | 2 | 2.0 |
Heat | 2 | 0.0 |
Proteins/chemistry/genetics | 2 | 7.0 |
*Saccharomyces cerevisiae Proteins | 6 | 0.0 |
Neurofibromatosis 1/*diagnosis/genetics | 11 | 100.0 |
Bucladesine/pharmacology | 3 | 1.0 |
In Vitro | 9 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 6 | 0.0 |
Cell Adhesion | 3 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
Genes, Tumor Suppressor/*physiology | 3 | 2.0 |
RNA, Messenger/*genetics | 7 | 1.0 |
Fluorodeoxyglucose F18/*diagnostic use | 2 | 15.0 |
Deoxyribonucleases, Type II Site-Specific | 6 | 2.0 |
*Polymorphism, Restriction Fragment Length | 8 | 1.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 3 | 1.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Neurons/cytology/metabolism | 2 | 2.0 |
*Gene Frequency | 3 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
*Polymorphism, Genetic | 14 | 0.0 |
Schwann Cells/*pathology | 3 | 33.0 |
*Trigeminal Nerve | 2 | 66.0 |
DNA, Complementary | 11 | 0.0 |
Enhancer Elements (Genetics) | 11 | 2.0 |
Erythrocytes/enzymology | 2 | 0.0 |
Visual Acuity/physiology | 3 | 17.0 |
Electrophoresis/methods | 2 | 2.0 |
Protein p53/biosynthesis/genetics | 2 | 4.0 |
Neurofibromatosis 1/*diagnosis/epidemiology | 2 | 100.0 |
Body Height | 4 | 2.0 |
Cross-Sectional Studies | 4 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Growth/*physiology | 2 | 14.0 |
Chromosome Aberrations | 6 | 1.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
S100 Proteins/analysis | 5 | 2.0 |
Fundus Oculi | 2 | 2.0 |
Neurofibromatosis 1/diagnosis | 2 | 100.0 |
*Optic Chiasm | 6 | 100.0 |
Optic Nerve Glioma/genetics | 2 | 100.0 |
DNA Methylation | 6 | 0.0 |
Genes, p16 | 2 | 2.0 |
*Disease Models, Animal | 6 | 1.0 |
*Genes, p53 | 10 | 2.0 |
Sarcoma/genetics/*pathology | 2 | 100.0 |
Nerve Sheath Tumors/*genetics/*pathology | 2 | 66.0 |
Gene Rearrangement | 2 | 0.0 |
Physical Chromosome Mapping/*methods | 2 | 10.0 |
Repetitive Sequences, Nucleic Acid | 10 | 1.0 |
Body Weight | 2 | 0.0 |
Neurofibromatosis 1/genetics/*physiopathology | 3 | 75.0 |
Neurons/*physiology | 2 | 1.0 |
Proteins/genetics/*physiology | 4 | 3.0 |
Genetic Predisposition to Disease/genetics | 5 | 1.0 |
Acute Disease | 6 | 0.0 |
Endoscopy/*methods | 2 | 22.0 |
Gadolinium/diagnostic use | 2 | 12.0 |
Hydrocephalus/etiology/radiography/*surgery | 2 | 100.0 |
Neurofibromatoses/complications/radiography/*surgery | 2 | 100.0 |
Third Ventricle/*surgery | 2 | 100.0 |
Ventriculostomy | 2 | 66.0 |
*Chromosome Mapping | 25 | 1.0 |
Turkey | 2 | 1.0 |
von Willebrand Factor/*genetics | 2 | 2.0 |
Enzyme Inhibitors/pharmacology | 7 | 0.0 |
Half-Life | 3 | 0.0 |
Proteins/*metabolism | 8 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Parents | 4 | 5.0 |
Mosaicism | 4 | 5.0 |
Neurofibroma/genetics/*pathology | 2 | 100.0 |
CCAAT-Enhancer-Binding Proteins | 4 | 2.0 |
Nuclear Proteins/genetics/metabolism | 3 | 1.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Brain/*pathology | 4 | 2.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
*Trans-Activation (Genetics) | 4 | 0.0 |
Neoplasms, Experimental/genetics | 2 | 15.0 |
*Phenotype | 2 | 0.0 |
Military Personnel | 2 | 6.0 |
Codon, Nonsense/genetics | 2 | 3.0 |
Glioma/genetics | 2 | 9.0 |
Brain/pathology | 14 | 4.0 |
Neurofibromatosis 1/*psychology | 6 | 100.0 |
Neurofibroma/pathology | 3 | 42.0 |
GTPase-Activating Proteins | 40 | 25.0 |
Proteins/*genetics/metabolism | 9 | 3.0 |
ras GTPase-Activating Proteins | 33 | 30.0 |
Nerve Sheath Tumors/*metabolism | 2 | 100.0 |
*Protein Biosynthesis | 11 | 2.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
*Chorionic Villi Sampling | 2 | 8.0 |
Fetal Diseases/diagnosis/genetics | 3 | 30.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Chromatin/metabolism | 2 | 0.0 |
Nucleic Acid Conformation | 11 | 2.0 |
Transcription Factors/genetics | 5 | 0.0 |
Proteins/*genetics/*metabolism | 3 | 4.0 |
Audiometry, Pure-Tone | 3 | 7.0 |
*CpG Islands | 2 | 2.0 |
DNA/*metabolism | 2 | 0.0 |
DNA/genetics/*metabolism | 3 | 4.0 |
Multigene Family/*genetics | 2 | 1.0 |
*Body Height | 2 | 4.0 |
*Cephalometry | 2 | 66.0 |
Child Development | 2 | 10.0 |
Spain | 2 | 0.0 |
Cell Cycle | 3 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
Reoperation | 2 | 1.0 |
*Genes | 4 | 1.0 |
Linkage (Genetics)/*genetics | 4 | 1.0 |
Chromosome Aberrations/*genetics | 4 | 2.0 |
Cell Division/genetics | 3 | 0.0 |
Neurofibromatosis 1/pathology | 3 | 60.0 |
Disease Susceptibility | 4 | 0.0 |
Questionnaires | 2 | 0.0 |
Fibroblast Growth Factor 2/pharmacology | 5 | 2.0 |
Skin/metabolism/pathology | 2 | 4.0 |
Brain Neoplasms/complications/pathology | 2 | 100.0 |
Chromosome Aberrations/genetics | 4 | 3.0 |
Chromosome Disorders | 9 | 2.0 |
Nuclear Family | 2 | 0.0 |
Ki-67 Antigen/*metabolism | 2 | 4.0 |
Bone Marrow Cells | 2 | 0.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
*Mutagenesis, Insertional | 4 | 11.0 |
*Virus Integration | 2 | 2.0 |
Neurofibromatosis 1/*radiography | 3 | 100.0 |
DNA Probes | 14 | 1.0 |
Repressor Proteins/*metabolism | 2 | 1.0 |
Models, Molecular | 5 | 0.0 |
*Protein Structure, Tertiary | 2 | 1.0 |
Proteins/*chemistry | 2 | 2.0 |
Biopsy, Needle | 4 | 0.0 |
Nerve Sheath Tumors/*pathology | 2 | 50.0 |
Neurilemmoma/*pathology | 2 | 28.0 |
Stromal Cells/pathology | 2 | 3.0 |
Psychiatric Status Rating Scales | 2 | 0.0 |
Codon, Terminator | 2 | 3.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/*physiology | 4 | 2.0 |
Genes, Tumor Suppressor/*genetics | 4 | 1.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Genes, ras/*genetics | 6 | 6.0 |
Protein Isoprenylation | 2 | 2.0 |
Signal Transduction/*genetics | 3 | 2.0 |
Transferases/antagonists & inhibitors | 2 | 66.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Bone Diseases, Developmental/diagnosis | 2 | 100.0 |
DNA/chemistry | 2 | 0.0 |
RNA, Messenger | 3 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Radiography, Panoramic | 2 | 40.0 |
Cerebellum/metabolism/pathology | 2 | 22.0 |
Cerebral Cortex/metabolism/pathology | 2 | 11.0 |
Remission, Spontaneous | 3 | 4.0 |
*Genes, Dominant | 4 | 1.0 |
Translocation, Genetic/genetics | 3 | 3.0 |
Tretinoin/pharmacology | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
DNA-Binding Proteins/isolation & purification/*metabolism | 5 | 7.0 |
Hamsters | 11 | 0.0 |
*Suppression, Genetic | 2 | 7.0 |
4-Aminopyridine/pharmacology | 2 | 13.0 |
Patch-Clamp Techniques | 3 | 0.0 |
Potassium/*metabolism | 2 | 4.0 |
Schwann Cells/*metabolism | 6 | 37.0 |
Tetraethylammonium/pharmacology | 2 | 9.0 |
Pseudogenes | 7 | 3.0 |
Cafe-au-Lait Spots/diagnosis | 2 | 100.0 |
GTP Phosphohydrolases/*metabolism | 6 | 5.0 |
DNA | 12 | 1.0 |
Proteins/*physiology | 4 | 2.0 |
Leukemia, Myeloid, Chronic/*genetics | 4 | 6.0 |
Nerve Growth Factors/pharmacology | 4 | 4.0 |
Platelet-Derived Growth Factor/*pharmacology | 2 | 2.0 |
Stem Cell Factor/pharmacology | 3 | 2.0 |
Transcription Factors/metabolism | 15 | 1.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 6 | 0.0 |
Neurofibromatosis 1/complications | 3 | 60.0 |
Proportional Hazards Models | 2 | 0.0 |
Survival Analysis | 4 | 0.0 |
Attitude to Health | 2 | 4.0 |
Practice Guidelines | 2 | 2.0 |
Dogs/*genetics | 2 | 4.0 |
Orbit/*pathology | 2 | 40.0 |
Neurofibromatosis 1/*diagnosis/epidemiology/*physiopathology | 2 | 100.0 |
Nerve Tissue Proteins/metabolism | 2 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Brain/*metabolism | 4 | 0.0 |
PC12 Cells | 2 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 6 | 1.0 |
Brain Neoplasms/genetics/*pathology | 2 | 28.0 |
Neurofibromatoses/*pathology | 2 | 100.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
*Genome, Human | 2 | 0.0 |
*Chromosomes, Human, Pair 15 | 2 | 0.0 |
Mental Retardation/etiology | 3 | 30.0 |
Optic Nerve Neoplasms/etiology | 3 | 100.0 |
Neurofibromatosis 1/genetics/radiography/*surgery | 2 | 100.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Neurofibromin 1/chemistry/*genetics | 2 | 100.0 |
Learning Disorders/*genetics | 3 | 30.0 |
Centromere | 2 | 2.0 |
Telomere/genetics | 2 | 3.0 |
Molecular Weight | 6 | 0.0 |
Tritium | 2 | 0.0 |
Brain Neoplasms/*genetics/pathology | 3 | 4.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Proto-Oncogene Protein p21(ras)/*metabolism | 4 | 9.0 |
Histones/genetics/*metabolism | 2 | 13.0 |
Mammary Tumor Virus, Mouse/*genetics | 4 | 28.0 |
Molecular Structure | 2 | 0.0 |
Nucleosomes/*metabolism | 3 | 8.0 |
Abnormalities, Multiple/*genetics | 3 | 0.0 |
Genetic Diseases, Inborn | 2 | 13.0 |
Homozygote | 8 | 0.0 |
Neurofibromin 2/*metabolism | 2 | 33.0 |
Electroencephalography | 3 | 1.0 |
Mammals | 3 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Liver/*chemistry | 2 | 5.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Hippel-Lindau Disease/*genetics | 3 | 2.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
Frameshift Mutation/*genetics | 2 | 3.0 |
Genes, Neurofibromatosis 2/genetics | 4 | 30.0 |
Thermodynamics | 2 | 0.0 |
Abdominal Neoplasms/*genetics | 2 | 33.0 |
Chromosomes, Human, Pair 1/*genetics | 2 | 0.0 |
Gene Amplification | 2 | 0.0 |
Neuroblastoma/*genetics | 8 | 8.0 |
Noonan Syndrome/*genetics | 2 | 16.0 |
DNA-Binding Proteins/metabolism/*physiology | 3 | 2.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Genetic Vectors | 6 | 0.0 |
Trans-Activation (Genetics) | 5 | 0.0 |
Enhancer Elements (Genetics)/*genetics | 2 | 2.0 |
Chickens | 4 | 0.0 |
Erythrocytes/metabolism | 2 | 1.0 |
Receptors, Estrogen/genetics/*metabolism | 2 | 5.0 |
DNA, Complementary/genetics | 8 | 0.0 |
In Situ Hybridization, Fluorescence/methods | 3 | 3.0 |
Maternal Age | 2 | 2.0 |
Genes, Neurofibromatosis 2/*genetics | 2 | 4.0 |
Neurofibromatosis 1/*pathology/radiography | 3 | 100.0 |
DNA-Binding Proteins/genetics/metabolism | 5 | 1.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Brain Stem/*pathology | 2 | 18.0 |
Neurologic Examination | 4 | 3.0 |
Cell Division/physiology | 4 | 0.0 |
Neurofibroma/chemistry | 2 | 100.0 |
Recombination, Genetic | 14 | 1.0 |
Puberty, Precocious/*etiology | 2 | 50.0 |
Chromosomes, Human, Pair 1 | 4 | 1.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
Deoxyribonuclease HpaII | 2 | 2.0 |
Restriction Mapping | 28 | 1.0 |
X Chromosome | 3 | 0.0 |
*DNA Transposable Elements | 3 | 5.0 |
Nucleic Acid Heteroduplexes/chemistry | 2 | 33.0 |
Adrenal Gland Neoplasms/genetics | 2 | 7.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Adenine Nucleotide Translocator 2/*genetics | 2 | 100.0 |
Gene Silencing | 2 | 0.0 |
Iris/*pathology | 2 | 100.0 |
Family Planning Services | 2 | 25.0 |
*Prenatal Diagnosis | 4 | 1.0 |
Gene Expression Regulation, Viral | 4 | 1.0 |
Proto-Oncogenes | 2 | 1.0 |
*Genomic Imprinting | 2 | 0.0 |
Registries | 2 | 0.0 |
Sweden/epidemiology | 2 | 1.0 |
*ras GTPase-Activating Proteins | 2 | 5.0 |
DNA Transposable Elements | 4 | 2.0 |
*Chromosome Disorders | 2 | 2.0 |
Chi-Square Distribution | 2 | 0.0 |
Glioma/*epidemiology | 2 | 100.0 |
*Cognition | 2 | 4.0 |
Hybridization, Genetic | 2 | 3.0 |
Genes, ras | 11 | 4.0 |
*Monosomy | 2 | 6.0 |
Physical Examination | 2 | 7.0 |
Family | 4 | 1.0 |
Brain Neoplasms/diagnosis | 2 | 33.0 |
Analysis of Variance | 6 | 0.0 |
Growth Substances/*pharmacology | 3 | 0.0 |
Melanocytes/*metabolism | 3 | 7.0 |
Cosmids | 5 | 1.0 |
Brain Neoplasms/*physiopathology | 2 | 11.0 |
Astrocytoma/genetics | 2 | 8.0 |
Pheochromocytoma/genetics | 2 | 8.0 |
*RNA Editing | 2 | 4.0 |
Liver | 4 | 7.0 |
Receptors, Glucocorticoid/*metabolism | 2 | 7.0 |
*Alkyl and Aryl Transferases | 3 | 12.0 |
Neurofibromatosis 1/*pathology/physiopathology | 2 | 100.0 |
*Neoplasm Proteins | 2 | 0.0 |
DNA, Viral/genetics/metabolism | 4 | 13.0 |
*Gene Expression Regulation, Viral | 4 | 1.0 |
JC Virus/*genetics | 3 | 30.0 |
*Repetitive Sequences, Nucleic Acid | 7 | 1.0 |
Pigmentation Disorders/etiology | 2 | 66.0 |
Nucleic Acid Heteroduplexes/*genetics | 2 | 15.0 |
DNA, Satellite | 2 | 7.0 |
Genomic Imprinting | 2 | 1.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Chromosomes | 2 | 2.0 |
Neurofibromatosis 1/*complications/genetics | 4 | 100.0 |
Bone Marrow/*metabolism | 2 | 4.0 |
DNA, Viral | 4 | 2.0 |
*Retroelements | 2 | 9.0 |
Cell Lineage | 3 | 0.0 |
*DNA Mutational Analysis | 3 | 1.0 |
Prenatal Diagnosis | 3 | 1.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
*Genes, Structural | 5 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Neurofibromatosis 2/*genetics | 6 | 8.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 3 | 2.0 |
Deoxyribonuclease I | 5 | 3.0 |
Recombinant Proteins/biosynthesis | 4 | 0.0 |
Genes, Neurofibromatosis 1/*physiology | 6 | 100.0 |
RNA Splicing | 5 | 0.0 |
DNA-Binding Proteins/biosynthesis/*metabolism | 2 | 3.0 |
Methylation | 4 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Neurofibromatosis 2/*diagnosis/genetics | 2 | 25.0 |
Neurofibromatosis 1/genetics/*psychology | 2 | 100.0 |
Arteries/pathology | 2 | 18.0 |
Brain/physiopathology | 2 | 3.0 |
Linkage (Genetics)/genetics | 4 | 1.0 |
Glioblastoma/genetics | 2 | 6.0 |
Proteins/analysis | 2 | 1.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Sex Distribution | 3 | 1.0 |
*DNA, Viral | 2 | 14.0 |
Gadolinium DTPA | 2 | 16.0 |
Organometallic Compounds/diagnostic use | 2 | 16.0 |
Proteins/genetics/*metabolism | 8 | 1.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-raf | 4 | 3.0 |
Psychometrics | 2 | 3.0 |
DNA Probes/genetics | 4 | 3.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Israel/epidemiology | 2 | 4.0 |
Gene Library | 7 | 0.0 |
Cytosine/metabolism | 2 | 5.0 |
Substrate Specificity | 2 | 0.0 |
Evolution | 4 | 1.0 |
*Introns | 4 | 1.0 |
Age of Onset | 4 | 0.0 |
Guanosine Diphosphate/metabolism | 2 | 1.0 |
Signal Transduction/physiology | 3 | 0.0 |
ras Proteins/metabolism/*physiology | 2 | 66.0 |
Genetic Heterogeneity | 2 | 0.0 |
Likelihood Functions | 2 | 1.0 |
*Enhancer Elements (Genetics) | 5 | 1.0 |
Fibroblasts/cytology | 3 | 1.0 |
Sequence Analysis | 2 | 0.0 |
Self-Help Groups | 2 | 18.0 |
GTP Phosphohydrolases/metabolism | 8 | 5.0 |
DNA Restriction Enzymes | 4 | 1.0 |
Polymerase Chain Reaction/*methods | 4 | 0.0 |
Epidermal Growth Factor/pharmacology | 3 | 0.0 |
Guanine Nucleotides/metabolism | 2 | 10.0 |
Skin Neoplasms/*genetics | 7 | 5.0 |
Cell Transformation, Neoplastic/*genetics | 3 | 1.0 |
Oncogenes | 2 | 0.0 |
Chromatin/*metabolism | 2 | 1.0 |
Xenopus laevis | 4 | 0.0 |
Nerve Sheath Tumors/genetics | 2 | 100.0 |
Nervous System Neoplasms/*genetics | 2 | 18.0 |
Brain Neoplasms/*genetics | 4 | 2.0 |
Ependymoma/genetics | 2 | 22.0 |
Leukemia, Myelocytic, Acute/*genetics | 2 | 1.0 |
Myelodysplastic Syndromes/*genetics | 2 | 2.0 |
Germ-Line Mutation/*genetics | 2 | 1.0 |
Codon/genetics | 4 | 1.0 |
Astrocytoma/*genetics | 4 | 8.0 |
Glioblastoma/*genetics | 2 | 2.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Adrenal Gland Neoplasms/*genetics | 3 | 10.0 |
Proviruses/genetics | 2 | 3.0 |
ras Proteins/*metabolism | 3 | 1.0 |
Melanocytes/metabolism | 2 | 5.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
*Monomeric GTP-Binding Proteins | 2 | 4.0 |
*Nucleoside-Diphosphate Kinase | 2 | 3.0 |
Receptors, Glucocorticoid/metabolism | 3 | 5.0 |
Receptors, Progesterone/metabolism | 2 | 1.0 |
Cognition Disorders/*diagnosis/epidemiology | 2 | 66.0 |
Wechsler Scales | 2 | 12.0 |
Conserved Sequence | 4 | 0.0 |
RNA, Messenger/*genetics/metabolism | 2 | 2.0 |
Mathematics | 2 | 1.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/metabolism | 2 | 2.0 |
Vitellogenins/*genetics | 2 | 66.0 |
Cricetulus | 3 | 0.0 |
DNA, Viral/metabolism | 2 | 2.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Neurofibromatosis 1/genetics/*metabolism | 3 | 100.0 |
Skin/cytology | 2 | 1.0 |
Cercopithecus aethiops | 3 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Photography | 2 | 15.0 |
Reproducibility of Results | 3 | 0.0 |
DNA/isolation & purification | 2 | 1.0 |
Chromosomes, Human, Pair 4 | 2 | 1.0 |
Neurilemmoma/*genetics | 3 | 15.0 |
DNA/genetics/isolation & purification | 7 | 2.0 |
Promoter Regions (Genetics)/*drug effects | 2 | 4.0 |
Escherichia coli/genetics | 3 | 0.0 |
*Chromosomes, Human, Pair 21 | 2 | 1.0 |
Leukemia, Myeloid/genetics | 2 | 5.0 |
Proteins/genetics/physiology | 2 | 3.0 |
Genes, Structural | 2 | 0.0 |
Mice/*genetics | 2 | 0.0 |
Monosomy | 2 | 6.0 |
Gestational Age | 2 | 0.0 |
Skin Neoplasms/genetics/*pathology | 2 | 18.0 |
Fungal Proteins/genetics | 2 | 1.0 |
Cytosine | 2 | 2.0 |
Thymidine | 2 | 28.0 |
Genetic Screening/*methods | 2 | 1.0 |
Neurofibromin 1/genetics/*metabolism | 5 | 100.0 |
Genes, myc/*genetics | 2 | 2.0 |
*Myelin-Associated Glycoprotein | 2 | 16.0 |
Papillomavirus/*genetics | 3 | 16.0 |
*ras Proteins | 3 | 33.0 |
*Neoplasms, Multiple Primary | 2 | 16.0 |
Central Nervous System Neoplasms/*genetics | 2 | 14.0 |
Eye Neoplasms/genetics | 2 | 15.0 |
Genetic Complementation Test | 3 | 0.0 |
Proteins/chemistry/*genetics/physiology | 2 | 11.0 |
Carcinoma, Small Cell/*genetics | 2 | 3.0 |
Ring Chromosomes | 2 | 15.0 |
*X Chromosome | 2 | 0.0 |
Neuroblastoma/*metabolism/pathology | 2 | 5.0 |
Neurofibromatosis 1/complications/*genetics/pathology | 3 | 100.0 |
Autoradiography | 2 | 0.0 |
DNA, Neoplasm/genetics/isolation & purification | 3 | 2.0 |
RNA/genetics/isolation & purification | 3 | 2.0 |
RNA, Neoplasm/genetics/isolation & purification | 2 | 3.0 |
DNA/*genetics | 6 | 1.0 |
Repetitive Sequences, Nucleic Acid/genetics | 2 | 2.0 |
Genes | 5 | 2.0 |
Proteins/physiology | 2 | 1.0 |
Neurofibromatosis 1/metabolism/*pathology | 2 | 66.0 |
Recombinant Fusion Proteins/immunology | 2 | 1.0 |
Skin Diseases/*genetics | 2 | 11.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 2 | 1.0 |
Genes, Viral | 4 | 1.0 |
Genes, Regulator | 2 | 1.0 |
*Genetic Markers | 9 | 2.0 |
Rats, Inbred Strains | 2 | 0.0 |
Transcription Initiation Site | 3 | 2.0 |
Antigens, Viral/*genetics | 2 | 11.0 |
Cytomegalovirus/*genetics | 4 | 10.0 |
*Immediate-Early Proteins | 2 | 0.0 |
Luciferases/genetics/metabolism | 3 | 1.0 |
Oncogene Protein p21(ras)/*metabolism | 2 | 13.0 |
*RNA Processing, Post-Transcriptional | 2 | 3.0 |
Neurofibromatosis 1/*complications/genetics/pathology | 2 | 100.0 |
Saccharomyces cerevisiae/*genetics | 2 | 1.0 |
Mosaicism/*genetics | 2 | 5.0 |
Phosphoproteins/*genetics | 2 | 0.0 |
Suppression, Genetic | 2 | 3.0 |
*Chromosomes, Human, Pair 17/ultrastructure | 3 | 42.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
*Image Processing, Computer-Assisted | 2 | 4.0 |
CCAAT-Enhancer-Binding Proteins/metabolism | 3 | 7.0 |
Swine | 2 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/metabolism | 2 | 3.0 |
Plasmids/genetics | 2 | 0.0 |
Logistic Models | 2 | 0.0 |
Chromatin/*genetics/*metabolism | 2 | 40.0 |
